Modifier gene therapy – clinical development and manufacturing considerations
European Pharmaceutical Review
JUNE 13, 2024
Ocugen is currently enrolling patients in the Phase I/II ArMaDa clinical trial to assess the safety and efficacy of OCU410 for GA secondary to dAMD. The ArMaDa clinical trial will assess the safety and efficacy of unilateral subretinal administration of OCU410 in subjects with GA and will be conducted in two phases.
Let's personalize your content